News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Concerns Cause OvaScience (OVAS) to Halt U.S. Trial of Souped-Up IVF Procedure; Stock Plunges -23.29% at Market Close (September 11, 2013)


9/11/2013 7:50:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Shares of OvaScience (NASDAQ: OVAS) were sent spiraling downward late Tuesday after the company revealed that the FDA wants it to seek regulatory approval for its lead product, Augment, a procedure designed to boost the success rate of in vitro fertilization. Cambridge, MA-based OvaScience received a letter from the FDA questioning the status of Augment as a human cellular tissue-based product, or HCT/P. Instead, the agency wants OvaScience to file an investigational new drug application.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at BusinessWeek
Read at Reuters

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES